Hydrocodin (Dihydrocodeine Tartrate)

Hydrocodin is prescribed for specific therapeutic purposes where opioid analgesia or cough suppression is required.

• Management of moderate to severe acute pain when non‑opioid analgesics are insufficient.
• Short‑term relief of chronic pain conditions under specialist guidance.
• Suppression of persistent, non‑productive cough associated with respiratory irritation.
• Adjunctive therapy for postoperative pain management.
• Use in palliative care settings to improve comfort when pain or cough is refractory.
• Treatment of severe cough episodes in patients with chronic obstructive pulmonary disease when other antitussives have failed.
• Short‑duration use for breakthrough pain in cancer patients already receiving opioid therapy.

• Dihydrocodeine tartrate acts as an agonist at the μ‑opioid receptors in the central nervous system. By binding to these G‑protein‑coupled receptors, it inhibits the release of neurotransmitters involved in pain transmission and reduces the cough reflex arc in the brainstem. The activation of μ‑receptors leads to decreased neuronal excitability, producing analgesia and antitussive effects while also influencing respiratory drive at higher doses.

Adverse reactions to Hydrocodin may vary in frequency and severity; they are reported in clinical use and pharmacovigilance data. These events are typically dose‑related and may be influenced by individual health status, concurrent medications, and the duration of therapy.

Common

• Nausea, vomiting, or stomach discomfort.
• Drowsiness, dizziness, or mild sedation.
• Constipation or reduced bowel motility.
• Dry mouth and mild itching.
• Headache or mild visual disturbances.
• Sweating or feeling of warmth.

Serious

• Respiratory depression, especially with high doses or concomitant depressants.
• Severe hypotension or cardiovascular collapse.
• Dependence, tolerance, or withdrawal symptoms on discontinuation.
• Allergic reactions such as rash, urticaria, or anaphylaxis.
• Seizures or convulsions.
• Severe gastrointestinal bleeding.

When prescribing Hydrocodin, clinicians consider several safety precautions to minimize risks and ensure appropriate use.

• Assess patient history for respiratory disorders, such as asthma or chronic obstructive pulmonary disease.
• Evaluate for signs of substance misuse, dependence, or a personal/family history of opioid addiction.
• Use the lowest effective dose for the shortest duration necessary to achieve therapeutic goals.
• Avoid prescribing to patients with known hypersensitivity to dihydrocodeine or other opioid analgesics.
• Monitor closely in the elderly, patients with hepatic or renal impairment, and those taking central nervous system depressants.
• Counsel patients on the potential for sedation, impaired coordination, and the importance of not operating machinery or driving.

Hydrocodin can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Concomitant use with other central nervous system depressants such as benzodiazepines, barbiturates, or alcohol, which may cause profound respiratory depression.
• Co‑administration with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy, due to risk of severe serotonin syndrome.
• Use with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can markedly increase dihydrocodeine plasma concentrations.

Use with caution

• Concurrent opioid therapy; dose adjustments and close monitoring are required to avoid additive effects.
• Combination with serotonergic agents (e.g., SSRIs, SNRIs, tramadol) may increase the risk of serotonin syndrome; monitor for symptoms.
• Patients receiving diuretics or antihypertensives should be observed for enhanced hypotensive effects.